EPA:GNFT Genfit - GNFT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Genfit S.A. Please log in to your account or sign up in order to add this asset to your watchlist. €3.63 +0.01 (+0.28%) (As of 03/28/2023 12:00 AM ET) Add Compare Share Share Today's Range€3.61▼€3.6650-Day Range€3.62▼€4.3852-Week Range N/AVolume37,265 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsHeadlines About Genfit (EPA:GNFT) StockGenfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.Read More Receive GNFT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter. Email Address GNFT Stock News HeadlinesMarch 19, 2023 | americanbankingnews.comGenfit (EPA:GNFT) Trading Up 0.9%March 1, 2023 | finance.yahoo.comGENFIT Announces Revenues and Cash Position as of December 31, 2022March 29, 2023 | Investing Daily (Ad)A 100% Win Rate In 2022…The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. January 3, 2023 | msn.comFinancial, Pharma Gains Spur European Equities Higher in Tuesday TradingJanuary 1, 2023 | thestreet.comGenfit's Fatty Liver Drug Study Results Are Coming. Here's What You Need to Know.November 18, 2022 | technews.tmcnet.comGENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver DiseasesNovember 10, 2022 | finance.yahoo.comGENFIT Reports Third Quarter 2022 Financial InformationOctober 27, 2022 | msn.comEuropean ADRs Move Higher in Wednesday TradingMarch 29, 2023 | Investing Daily (Ad)A 100% Win Rate In 2022…The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. October 12, 2022 | reuters.comGNFT.O - Genfit SA (ADR) | Stock Price & Latest News | ReutersJune 14, 2022 | seekingalpha.comGNFT Genfit S.A.May 25, 2022 | finance.yahoo.comGENFIT: May 25, 2022 Combined Shareholders Meeting resultsMay 11, 2022 | seekingalpha.comGenfit reports Q1 resultsMay 11, 2022 | finance.yahoo.comGENFIT Reports First Quarter 2022 Financial Information (Unaudited financial information under IFRS)April 29, 2022 | finance.yahoo.comGENFIT Announces Publication of the 2021 Universal Registration Document; the 2021 Annual Report on Form 20-F and Availability of Preparatory Documents for the Annual Combined Shareholders Meeting on May 25, 2022April 14, 2022 | finance.yahoo.comWhat Makes GENFIT S.A. Unsponsored ADR (GNFT) a New Buy StockApril 11, 2022 | benzinga.comSVB Leerink Maintains Outperform on Genfit, Lowers Price Target to $10April 7, 2022 | seekingalpha.comGenfit GAAP EPS of €1.23, revenue of €85.58MApril 7, 2022 | nz.finance.yahoo.comGENFIT Reports Full-Year 2021 Financial Results and Provides Corporate UpdateJanuary 25, 2022 | nasdaq.comGENFIT S.A. American Depositary Shares (GNFT)January 11, 2022 | finance.yahoo.comCan GENFIT S.A. Unsponsored ADR (GNFT) Climb 79% to Reach the Level Wall Street Analysts Expect?December 17, 2021 | msn.comWhy Genfit Shares Are RisingDecember 17, 2021 | markets.businessinsider.comPre-market Movers: GNFT, ABEO, SPRB, IO, CERN…December 17, 2021 | msn.comThe Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, ArgenxJune 30, 2021 | finance.yahoo.comGENFIT: June 30, 2021 Annual Shareholders Meeting resultsJune 25, 2021 | benzinga.comGENFIT Highlights 2 Poster Presentations At 2 Scientific/Medical Events In Jun.June 23, 2021 | finance.yahoo.comGENFIT presents new NIS4® data in NASH at the International Liver Congress™ and the 81st Scientific Sessions of the American Diabetes AssociationSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GNFT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeEPA Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolEPA:GNFT CUSIPN/A CIKN/A Webwww.genfit.com Phone33 3 20 16 40 00FaxN/AEmployees122Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesMr. Jean-Francois Mouney (Age 67)Co-Founder & Chairman Comp: $332.42kMr. M. Pascal Prigent (Age 54)Chief Exec. Officer Comp: $503.74kProf. Bart Staels (Age 59)Co-Founder & Chairman of the Scientific Advisory Board Mr. Thomas Baetz (Age 48)Chief Financial Officer Mr. Pascal Caisey (Age 54)Chief Operating Officer Dr. Dean W. Hum Ph.D. (Age 60)Chief Scientific Officer Mr. Laurent Lannoo (Age 52)Corp. Sec. & Director of Legal Affairs Ms. Stefanie Magner (Age 41)Chief Compliance Officer & VP of International Legal Affairs Ms. Emilie Desodt (Age 39)Vice-Pres of HR Mr. Jean-Christophe Marcoux (Age 45)Chief Strategy Officer More ExecutivesKey CompetitorsBayer AktiengesellschaftFRA:BAYNEssilor International Société AnonymeEPA:EIFresenius SE & Co. KGaAFRA:FREMERCK Kommanditgesellschaft auf AktienFRA:MRKSanofiEPA:SANView All Competitors GNFT Stock - Frequently Asked Questions How have GNFT shares performed in 2023? Genfit's stock was trading at €3.97 at the start of the year. Since then, GNFT stock has decreased by 8.7% and is now trading at €3.62. View the best growth stocks for 2023 here. What other stocks do shareholders of Genfit own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genfit investors own include Alimentation Couche-Tard (ATD.B), Aecon Group (ARE), Algonquin Power & Utilities (AQN), Aptiv (APTV), American Tower (AMT), Advanced Micro Devices (AMD), Ambarella (AMBA), Albemarle (ALB), Adobe (ADBE) and Abbott Laboratories (ABT). What is Genfit's stock symbol? Genfit trades on the EPA under the ticker symbol "GNFT." What is Genfit's stock price today? One share of GNFT stock can currently be purchased for approximately €3.62. How many employees does Genfit have? The company employs 122 workers across the globe. How can I contact Genfit? Genfit's mailing address is Parc Eurasante 885 avenue Eugene Avinee, Loos, Hauts De France 59120. The official website for the company is www.genfit.com. The company can be reached via phone at 33 3 20 16 40 00. This page (EPA:GNFT) was last updated on 3/29/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.